Liver stiffness (Fibroscan®) is a predictor of all‐cause mortality in people with non‐alcoholic fatty liver disease
Open Access
- 27 September 2022
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 43 (1) , 90-99
Abstract
Background and aims: Progressive liver fibrosis related to non‐alcoholic fatty liver disease (NAFLD) is associated with all‐cause and liver‐related mortality. We assessed vibration‐controlled transient elastography (VCTE) as a predictor of mortality. Method: Data from patients who underwent VCTE for NAFLD at four large health services in Victoria, Australia between the years 2008 and 2019 were linked to state‐wide data registries. Cause of death (COD) and predictors of all‐cause mortality were subsequently analysed using descriptive statistics and Cox‐proportional regression analysis. Results: Of 7079 VCTE records submitted for data linkage, 6341 were matched via data registry linkage. There were 217 deaths over a 22 653 person‐year follow‐up. COD included malignancies other than hepatocellular carcinoma (HCC) (18.0%, n = 39), sepsis (16.1%, n = 35), decompensated liver disease (15.2%, n = 33), cardiac disease (15.2%, n = 33) and HCC 6.0% ( n = 13). Controlled attenuation parameter (CAP) was not associated with mortality in univariable analysis (HR = 1.00, CI 1.0–1.0, p = .488). Increased liver stiffness measurement (LSM) (HR 1.02 per kiloPascal, CI 1.01–1.03, p < .001), Charlson comorbidity index (CCI) (HR 1.32 for each point, CI 1.27–1.38, p < .001) and age (HR 1.05 per annum, CI 1.03–1.07, p < .001) were each associated with higher rates of all‐cause mortality in multivariable analysis. LSM ≥10 kPa suggestive of compensated advanced chronic liver disease (cACLD) was associated with mortality in multivariable analysis (HR 2.31, CI 1.73–3.09, p < .001). Conclusion: VCTE LSM, in addition to age and CCI, is independently associated with increased all‐cause mortality in a large cohort with NAFLD.Keywords
This publication has 40 references indexed in Scilit:
- Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general populationHeart, 2014
- A systematic review: Burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; Should we care?Atherosclerosis, 2013
- Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2013
- Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United StatesHepatology, 2012
- Determination of reliability criteria for liver stiffness evaluation by transient elastographyHepatology, 2012
- The controlled attenuation parameter (CAP): A novel tool for the non-invasive evaluation of steatosis using Fibroscan®Clinics and Research in Hepatology and Gastroenterology, 2012
- Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver DiseaseHepatology, 2010
- Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD)Digestive and Liver Disease, 2008
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987